Jennifer A. Lockridge

发表

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Keith Bowman, B. Polisky, L. Jeffs, 2005, Nature Biotechnology.

Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy

S. Seiffert, L. Cova, Jennifer A. Lockridge, 2017, Molecular therapy. Nucleic acids.

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

M. Rothenberg, Jennifer A. Lockridge, A. Sandler, 2005, Cancer Chemotherapy and Pharmacology.

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

E. Borden, J. Cowens, R. Ganapathi, 2005, Molecular Cancer Therapeutics.

Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex.

Jennifer A. Lockridge, Kim Hartsough, Lynn Machemer, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices.

K. Hillgren, J. Mcswiggen, Jennifer A. Lockridge, 2004, Journal of pharmaceutical and biomedical analysis.

Development of Pre-Clinical Models for Evaluating the Therapeutic Potential of Candidate siRNA Targeting STAT6

Jennifer A. Lockridge, S. Zinnen, J. Hopkin, 2014, PloS one.

Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness.

Edward S Boyden, Alan Horsager, Alapakkam P Sampath, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication

B. Polisky, J. Mcswiggen, Jennifer A. Lockridge, 2005, Hepatology.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Jennifer L Marlowe, Violetta Akopian, Priya Karmali, 2017, Nucleic acid therapeutics.

RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.

P. Kaiser, Q. Nguyen, H. Tabandeh, 2010, American journal of ophthalmology.

Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical development

Jennifer A. Lockridge, S. Zinnen, G. D. Healey, 2010, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness.

E. Boyden, W. Hauswirth, S. Boye, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.